Literature DB >> 1103606

Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension.

J I Drayer, P W Kloppenborg, J Festen, A van't Laar, T J Benraad.   

Abstract

The effects of chlorthalidone, spironolactone and propranolol in reducing blood pressure were compared in the same 11 normoreninemic hypertensive patients. All three drugs decreased the blood pressure significantly and no agent had a superior blood pressure-lowering effect. The blood pressure did not normalize. The data suggest that no one variable--volume factors, relative hyperactivity of the renin-aldosterone system or beta-adrenergic hyperactivity--is the prime mover in normoreninemic hypertension. Long-term treatment with chlorthalidone resulted in slight hyperreninism (26.3 +/- 4.9 ng-ml-1-3 hours-1) (mean +/- standard error) with concomitant changes in plasma aldosterone (23.0 +/- 3.2 ng-100 ml-1). The body weight decreased significantly (--1.8 kg, P less than 0.005). Plasma potassium concentrations were low (3.2 +/- 0.1 mEq-liter -1). Creatinine clearance was unimpaired (117 +/- 6 ml-min-1). Treatment with spironolactone resulted in more marked hyperreninism (47.0 +/- 14.3 ng-ml-1-3 hours-1) and hyperaldosteronism (61.9 +/-11.8 ng-100 ml-1). The body weight decreased significantly (--1.9 kg, P less than 0.004). Significant hyperkalemia occurred (4.4 +/- 0.1 mEq-liter-1). The glomerular filtration rate decreased significantly to 93 +/- 3 ml-min-1 (P less than 0.004). Treatment with propranolol resulted in marked suppression of the plasma renin activity (1.8 +/- 0.2 ng-ml-1-3 hours-1) and plasma aldosterone levels (8.9 +/- 1.3 ng-100 ml-1). A significant increase in body weight occurred (+2.3 kg, P less than 0.013). The plasma potassium concentration increased to a level not significantly different from the value found after treatment with spironolactone (4.2 +/- 0.1 mEq-liter-1). The creatinine clearance decreased significantly to 99 +/- 5 ml-min-1 (P less than 0.008). Hyperreninemia (by spironolactone and chlorthalidone), effective hyperaldosteronism (by chlorthalidone) and volume retention (by propranolol) are considered to represent expressions of mechanisms counteracting the depressor effects of these different pharmacologic maneuvers, leading to the maintenance of supranormal blood pressure.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1103606     DOI: 10.1016/0002-9149(75)90174-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Effects of salbutamol and metoprolol on plasma renin activity and plasma potassium of normal subjects and of hypertensive patients.

Authors:  A Salvetti; L Poli; F Arzilli; L Sassano; R Pedrinelli; M Motolese
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

2.  Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.

Authors:  P O Lim; R T Jung; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

3.  Effect of diuretic, beta-adrenoceptor blocking agent and their combination on elevated blood pressure and serum potassium: a cross-over study.

Authors:  P J Neuvonen; P J Pentikäinen; A J Jounela
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

Review 4.  Beta-blockers and renal function.

Authors:  R Wilkinson
Journal:  Drugs       Date:  1982-03       Impact factor: 9.546

5.  Lack of influence of beta adrenergic blockade on serum potassium during an infusion of potassium.

Authors:  S R Smith; M J Kendall; C Ryder; S Laugher
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Fixed combination of sotalol and hydrochlorothiazide in the treatment of uncomplicated hypertension.

Authors:  A Jäättelä
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Aldosterone and plasma renin activity in hyperthyroid rats: effects of propranolol and propylthiouracil.

Authors:  M Montiel; E Jiménez; J A Naváez; M Morell
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.